Like many in our Batten community, we are disappointed to hear that Amicus have chosen to discontinue their CLN6 program and now their CLN3 gene therapy programs. We are encouraged, however, to learn that Nationwide Children’s Hospital has expressed its commitment to continue moving both of these programs forward. We look forward to seeing the ongoing development of the programs, and plan to follow up with Nationwide to understand their plans for the CLN3 program and how BBDF might collaborate.

In the meantime, we continue working very hard to advance our Batten-1 study to Phase III enrollment and look forward to sharing another update on this with our community soon.

Leave a Reply

Your email address will not be published. Required fields are marked *